top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
5 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
18 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
18 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


A Life Saved: Woman in Remission for 18 Years After Pioneering CAR T-Cell Therapy for Neuroblastoma
In an inspiring breakthrough for cancer treatment, a woman who underwent an experimental immunotherapy trial as a child has now been in remission for 18 years. Diagnosed with neuroblastoma, an aggressive form of nerve tissue cancer typically seen in children under 5, she is believed to be the longest-surviving patient treated with CAR T-cell therapy. This life-changing therapy, which uses genetically engineered white blood cells to target cancer, was part of a clinical trial
Feb 18, 2025


Light-Induced Gene Therapy Using Nanoparticles Targets and Destroys Cancer Cells' Mitochondria
A groundbreaking new approach in cancer treatment has emerged, utilizing light to disable the mitochondria, the energy-producing organelles inside cancer cells. Researchers at Ohio State University have developed a targeted gene therapy using viral vectors, specifically engineered adeno-associated viruses (AAVs), that deliver genes designed to disrupt mitochondrial function directly to cancer cells. This therapy uses light to activate these genes, leading to the collapse of t
Feb 8, 2025


$430 Million Cell and Gene Therapy Center Set to Launch on Long Island, NY
Governor Kathy Hochul has announced New York Biogenesis Park, a $430 million cell and gene therapy hub set to transform the field on Long Island. Backed by a $150 million state investment, this 700,000-square-foot facility in Lake Success will focus on developing life-saving therapies, including treatments for cancer, genetic diseases, and chronic illnesses. The park will revolutionize medicine by repairing damaged DNA, modifying mutated genes, and engineering therapeutic cel
Dec 2, 2024


FDA Approves Stem Cell Therapy, Regenecyte, Shown to Help Chemotherapy Patients Recover Blood Count
The FDA has approved Regenecyte, an innovative therapy made from umbilical cord blood stem cells, to help rebuild blood and immune systems in patients with blood disorders or those recovering from intense treatments like chemotherapy. This breakthrough offers a promising option for patients needing healthy blood cell regeneration. Regenecyte uses stem cells collected from umbilical cords, which are highly adaptable and can grow into essential blood and immune cells. The treat
Nov 29, 2024
bottom of page


